8/9/2007 7:53:35 AM
LONDON, 9 August 2007 – Hikma Pharmaceuticals PLC (”Hikma”)(LSE: HIK)(DIFX: HIK), the multinational pharmaceuticals group, announces that it has agreed to acquire the entire issued share capital of Alkan Pharma (”Alkan”)(the “Company”), an Egyptian pharmaceuticals company, for a cash consideration of $60.5 million (EGP 342 million). The acquisition is scheduled to complete in the second half of 2007, subject to meeting certain regulatory requirements. The acquisition will be funded entirely by debt.
comments powered by